Here is an overview of what we consider to be the key website statistics and information:
Parameter name | Status | Comment |
---|---|---|
Website meta title | Valcyte® (valganciclovir hydrochloride) Patient Support | Search engines recommend title length of around 50-60 characters. The length of this title is 55. |
Meta description | Patient assistance for Valcyte® (valganciclovir hydrochloride), an antiviral medication for transplant patients who have a high chance of developing CMV disease. Indications: Adult patients: Valcyte® (valganciclovir hydrochloride) tablets are an antiviral prescription medication given to patients who have a high chance of developing cytomegalovirus (CMV) disease after receiving a heart, kidney, or kidney-pancreas transplant. Valcyte helps prevent CMV disease in these patients. Pediatric patients: Valcyte tablets or oral solution is prescribed for the prevention of CMV disease in patients that are 4 months to 16 years of age who have received a kidney transplant or in patients that are 1 month to 16 years of age who have received a heart transplant and have a high chance of developing CMV disease. Important Safety Information and Most Serious Side Effects Valcyte can affect blood cells and bone marrow causing serious and life- threatening problems. Patients’ doctors may do regular blood tests to check blood cells and may change the dose or tell patients to stop taking Valcyte. Patients must tell their doctor right away if they have any unexpected bruising or bleeding, unusual tiredness, fever, lack of energy, dizziness, or fainting. Valcyte may cause cancer. Valcyte causes cancer in animals. It is not known if Valcyte causes cancer in people. Valcyte may cause birth defects. Pregnant women who take Valcyte have a higher chance of having a baby with birth defects. Valcyte should not be used during pregnancy. Women who can get pregnant must use a reliable method of birth control during treatment with Valcyte and continue birth control for at least 30 days after they stop taking Valcyte. Women must tell their doctor right away if they get pregnant or plan to become pregnant while taking Valcyte. Men must use a condom during treatment with Valcyte, and for at least 90 days after treatment, if their partner can get pregnant. Patients should talk to their doctor if they have questions about birth control. Valcyte may lower the amount of sperm in a man’s body and cause fertility problems. Valcyte may also cause fertility problems in women. Patients should not take Cytovene-IV if they are taking Valcyte. Patients could overdose and become very sick if Valcyte is taken with Cytovene-IV. Patients should talk to their doctor or pharmacist if they have questions about their medicine. Patients should not receive Valcyte if they are allergic to any of its ingredients or if they have ever had a serious reaction to ganciclovir capsules or Cytovene-IV. Symptoms of an allergic reaction to Valcyte may include cold, sudden trouble breathing, wheezing, hives all over the body, swelling around the mouth, or feeling anxious. Valcyte can affect the kidneys, including serious problems such as kidney failure. Patients’ doctors may do regular blood tests to check kidney function while patients are taking Valcyte. The doctor may adjust the dose based on these tests. Patients must not take Valcyte tablets if they are receiving hemodialysis. Patients should talk to their doctor if they are receiving hemodialysis. Before starting Valcyte, patients should tell their doctor if they: • are pregnant or plan to become pregnant. It is not known if Valcyte causes birth defects in an unborn baby • are breastfeeding, or plan to breastfeed • have kidney problems or any other medical condition • have problems with their blood cells • are taking any prescription or non-prescription medicines, vitamins, and herbal supplements • are having radiation treatment • are receiving hemodialysis Valcyte can cause seizures, sleepiness, dizziness, and confusion. Patients should not drive a car or operate other dangerous machinery until they know how Valcyte affects them. Patients must take Valcyte exactly as their doctor prescribes it. Adult patients should use Valcyte tablets, not Valcyte for oral solution. Valcyte must be taken with food. Do not break or crush tablets. Common side effects of Valcyte in adults and children include: diarrhea, nausea, vomiting, fever, shaky movements (tremors), low blood cell counts in a blood test, and rejection of the transplanted organ (graft). Other common side effects in children include: headache, upper respiratory tract infection, and urinary tract infection. Patients should tell their doctor if they have any side effect that bothers them or that does not go away. Patients should call their doctor for medical advice about side effects. Consumers may report side effects to the FDA at 1-800-FDA-1088 or to Genentech at 1-888-835-2555. Please see full Prescribing Information, including Boxed WARNINGS, for additional Important Safety Information. | To make sure all the meta description is visible in search results page, Google recommends length of up to 320 characters at the most. This description has exactly 4713 characters. |
Load time | 2.1415 seconds on average | Load speed is a concern and should be improved if and when possible. |
Alexa global | 985 027, as last updated | According to Alexa, the website's popularity is not exactly high. Take this rank with a healthy pinch of salt. |
Quantcast global | 417 559 | The website's rank is quite poor. As with Alexa, QUANTCAST is not always perfectly representative of a website's performance. |
Total links on homepage | We found 34 links | This is a normal amount of links. |
Page HTML size | 29.1KB | How do we put this... improvement is quite necessary. Load speed is a very important factor in so many ways! |
Website server | Server appears to be online. The IP address for the server is 72.34.128.99. | It's unfortunate, but despite our best attempts, we failed to gather enough data to provide a meaningful insight at this time. |
What, all that information was not enough? You want... more? Right, then. You asked for it.
With over 4 million websites indexed (which can seem as a lot, or very little, depending on your point of view), Alexa is perhaps the oldest and certainly the best known ranking system, deservedly or not. The Alexa Global and Local ranks of a website are based on an approximate amount of visitors a given website receives. The more visitors, the higher the rank. The Alexa rank, be it Local or Global, should be taken with a pinch of salt. After all, visitor count is by far not the simple measure of a website's success it's made out to be. For example, a gardening website is never going to be as popular as a movie review website. It does not mean it's not popular within it's niche.
QUANTCAST - an advertising-related data processing company - mostly specializes in real-time audience analysis and measurements. In other words it, like Alexa, is basing its rankings on approximate traffic numbers. Currently, QUANTCAST has rated around 417 121 711 websites. Just like ALEXA, this is not a metric of huge importance, so don't base your SEO decisions on QUANTCAST rank, specifically. At best, it's a vague representation of how your website is doing in the grand scheme of things, but it does not take all that much context into account.
Similarly to how a hard drive or a modern SSD device holds your files, a server holds all the files the website needs to operate. To load a webpage, your browser needs to contact the said server and request files - strings of code that make up the website into what it is, including images, text and database entries. Each physical server has a unique IP address that is used by the browser to contact it.
Let's see what technical information we've managed to gather:
Header in detail |
---|
HTTP/1.1 200 OK Date: Fri, 08 Sep 2017 05:45:05 GMT Content-Disposition: inline;filename="index.html" Accept-Ranges: bytes ETag: /patient_1504806685218 Last-Modified: Thu, 07 Sep 2017 17:51:25 GMT Content-Range: bytes 0-29603/29603 Content-Length: 29603 Keep-Alive: timeout=1, max=100 Connection: close Content-Type: text/html;charset=UTF-8 Content-Language: en Set-Cookie: BIGipServerws_products_pool=!wVYPTRovEvNMkb7hZrY1cYfRyoiyA4vcb5bg5vtlCbczGEhE1o5qbBCP1wBIiQnLd+NnQj0ce9yjyw==; path=/ |
WHOIS information |
---|
Domain Name: VALCYTE.COM Registry Domain ID: 67217776_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.safenames.net Registrar URL: http://www.safenames.net Updated Date: 2017-04-01T04:09:46Z Creation Date: 2001-03-08T17:15:29Z Registry Expiry Date: 2019-03-08T17:15:29Z Registrar: SafeNames Ltd Registrar IANA ID: 447 Registrar Abuse Contact Email: Registrar Abuse Contact Phone: Domain Status: clientDeleteProhibited https://icann.org/epp#clientDeleteProhibited Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Domain Status: clientUpdateProhibited https://icann.org/epp#clientUpdateProhibited Name Server: HLRNS1.ROCHE.COM Name Server: NS1.ROCHE.COM Name Server: NS2.ROCHE.COM DNSSEC: unsigned URL of the ICANN Whois Inaccuracy Complaint Form: https://www.icann.org/wicf/ >>> Last update of whois database: 2017-09-08T04:37:41Z <<< For more information on Whois status codes, please visit https://icann.org/epp NOTICE: The expiration date displayed in this record is the date the registrar's sponsorship of the domain name registration in the registry is currently set to expire. This date does not necessarily reflect the expiration date of the domain name registrant's agreement with the sponsoring registrar. Users may consult the sponsoring registrar's Whois database to view the registrar's reported date of expiration for this registration. TERMS OF USE: You are not authorized to access or query our Whois database through the use of electronic processes that are high-volume and automated except as reasonably necessary to register domain names or modify existing registrations; the Data in VeriSign Global Registry Services' ("VeriSign") Whois database is provided by VeriSign for information purposes only, and to assist persons in obtaining information about or related to a domain name registration record. VeriSign does not guarantee its accuracy. By submitting a Whois query, you agree to abide by the following terms of use: You agree that you may use this Data only for lawful purposes and that under no circumstances will you use this Data to: (1) allow, enable, or otherwise support the transmission of mass unsolicited, commercial advertising or solicitations via e-mail, telephone, or facsimile; or (2) enable high volume, automated, electronic processes that apply to VeriSign (or its computer systems). The compilation, repackaging, dissemination or other use of this Data is expressly prohibited without the prior written consent of VeriSign. You agree not to use electronic processes that are automated and high-volume to access or query the Whois database except as reasonably necessary to register domain names or modify existing registrations. VeriSign reserves the right to restrict your access to the Whois database in its sole discretion to ensure operational stability. VeriSign may restrict or terminate your access to the Whois database for failure to abide by these terms of use. VeriSign reserves the right to modify these terms at any time. The Registry database contains ONLY .COM, .NET, .EDU domains and Registrars. |
A good domain address is usually one that is easy to spell, resulting in the smallest amount of mistypes possible. Still, such a thing inevitably happens. Here is a list with the most frequent 1794 mistypes, associated with valcyte.com:
If you are curious about what TLD extensions could also match the domain name of valcyte.com well, we have prepared an extensive list for you to look through:
We are glad you have finished this report. Hopefully, you found what you were looking for. In case you need more information to compare, here is a list of some other detailed overviews we have prepared: